Cyclin-dependent kinase 12 (CDK12), human kinase domain; a Target Enabling Package
A description of the materials and methods is included within the TEP datasheet. Cyclin-dependent kinase 12 (CDK12) phosphorylates RNA Pol II C-terminal domain (CTD) to promote transcriptional elongation of large DNA damage response genes. CDK12 is frequently mutated or amplified in cancer and its l...
| Main Author: | |
|---|---|
| Format: | Dataset |
| Published: |
University of Oxford
2018
|
| Subjects: |
| _version_ | 1797053705730654208 |
|---|---|
| author | Dixon-Clarke, S |
| author2 | Dixon-Clarke, S |
| author_facet | Dixon-Clarke, S Dixon-Clarke, S |
| author_sort | Dixon-Clarke, S |
| collection | OXFORD |
| description | A description of the materials and methods is included within the TEP datasheet. Cyclin-dependent kinase 12 (CDK12) phosphorylates RNA Pol II C-terminal domain (CTD) to promote transcriptional elongation of large DNA damage response genes. CDK12 is frequently mutated or amplified in cancer and its loss sensitises cells to DNA damage. Here we present 3 crystal structures of the human CDK12/CycK complex including apo, AMP-PNP and covalent inhibitor complexes. Kinase assays compare domain truncations and report the Km values for substrate. THZ531 is presented as a potent and selective inhibitor of CDK12 with nanomolar activity in leukemic cell lines. |
| first_indexed | 2024-03-06T18:47:26Z |
| format | Dataset |
| id | oxford-uuid:0efb2439-804b-41ac-b34c-648dde90a632 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T18:47:26Z |
| publishDate | 2018 |
| publisher | University of Oxford |
| record_format | dspace |
| spelling | oxford-uuid:0efb2439-804b-41ac-b34c-648dde90a6322022-03-26T09:49:02ZCyclin-dependent kinase 12 (CDK12), human kinase domain; a Target Enabling PackageDatasethttp://purl.org/coar/resource_type/c_ddb1uuid:0efb2439-804b-41ac-b34c-648dde90a632Chemical BiologyStructural GenomicsDrug DiscoveryORA DepositUniversity of Oxford2018Dixon-Clarke, SDixon-Clarke, SElkins, JHannett, NManz, THao, MBartkowiak, BGreenleaf, AMarto, JGeyer, MYoung, RGray, NMorin, GCheng, SZhang, TKwiatkowski, NOlson, CAbraham, BGreifenberg, AFicarro, SLiang, YA description of the materials and methods is included within the TEP datasheet. Cyclin-dependent kinase 12 (CDK12) phosphorylates RNA Pol II C-terminal domain (CTD) to promote transcriptional elongation of large DNA damage response genes. CDK12 is frequently mutated or amplified in cancer and its loss sensitises cells to DNA damage. Here we present 3 crystal structures of the human CDK12/CycK complex including apo, AMP-PNP and covalent inhibitor complexes. Kinase assays compare domain truncations and report the Km values for substrate. THZ531 is presented as a potent and selective inhibitor of CDK12 with nanomolar activity in leukemic cell lines. |
| spellingShingle | Chemical Biology Structural Genomics Drug Discovery Dixon-Clarke, S Cyclin-dependent kinase 12 (CDK12), human kinase domain; a Target Enabling Package |
| title | Cyclin-dependent kinase 12 (CDK12), human kinase domain; a Target Enabling Package |
| title_full | Cyclin-dependent kinase 12 (CDK12), human kinase domain; a Target Enabling Package |
| title_fullStr | Cyclin-dependent kinase 12 (CDK12), human kinase domain; a Target Enabling Package |
| title_full_unstemmed | Cyclin-dependent kinase 12 (CDK12), human kinase domain; a Target Enabling Package |
| title_short | Cyclin-dependent kinase 12 (CDK12), human kinase domain; a Target Enabling Package |
| title_sort | cyclin dependent kinase 12 cdk12 human kinase domain a target enabling package |
| topic | Chemical Biology Structural Genomics Drug Discovery |
| work_keys_str_mv | AT dixonclarkes cyclindependentkinase12cdk12humankinasedomainatargetenablingpackage |